12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Benzinga · 06/03 12:06
Gainers
- Picard Medical (AMEX:PMI) stock moved upwards by 30.7% to $0.35 during Wednesday's pre-market session. The company's market cap stands at $25.2 million.
- Relmada Therapeutics (NASDAQ:RLMD) stock increased by 15.41% to $7.41. The market value of their outstanding shares is at $673.3 million.
- Abivax (NASDAQ:ABVX) stock moved upwards by 15.17% to $83.5. The market value of their outstanding shares is at $5.7 billion.
- Connect Biopharma Hldgs (NASDAQ:CNTB) shares moved upwards by 13.48% to $2.44. The market value of their outstanding shares is at $135.3 million.
- QT Imaging Holdings (NASDAQ:QTI) shares increased by 12.61% to $5.0. The market value of their outstanding shares is at $58.7 million.
- Agape ATP (NASDAQ:ATPC) shares moved upwards by 12.12% to $3.33. The market value of their outstanding shares is at $2.9 million.
Losers
- Inotiv (NASDAQ:NOTV) shares declined by 40.4% to $0.15 during Wednesday's pre-market session. The company's market cap stands at $8.9 million.
- TransCode Therapeutics (NASDAQ:RNAZ) shares declined by 29.05% to $3.75. The market value of their outstanding shares is at $5.0 million.
- Soligenix (NASDAQ:SNGX) stock decreased by 19.88% to $0.6. The company's market cap stands at $11.1 million.
- Basel Medical Group (NASDAQ:BMGL) stock decreased by 19.56% to $0.44. The market value of their outstanding shares is at $10.3 million.
- AIM ImmunoTech (AMEX:AIM) shares fell 18.96% to $0.67. The market value of their outstanding shares is at $12.0 million.
- NRX Pharmaceuticals (NASDAQ:NRXP) stock declined by 18.84% to $3.75. The company's market cap stands at $167.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.